AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21462332 — intervention group
Group type: COMPARATOR
Intervention: Isolated coumarin in a capsule (reference)
Number of subjects: 24
Study 21462332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon in capsules
Number of subjects: 24
Study 21462332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon tea
Number of subjects: 24
Study 21462332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon in rice pudding
Number of subjects: 24
Study 18707693 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (switch method: direct switch or start-taper switch)
Number of subjects: 0
Study 18707693 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (start-taper switch)
Number of subjects: 0
Study 18707693 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (overall treatment)
Number of subjects: 0
Study 17580028 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease‐modulating dressing
Number of subjects: 40
Study 17580028 — intervention group
Group type: COMPARATOR
Intervention: Standardized protocol for good wound care (Control)
Number of subjects: 40
Study 15147430 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL‐ST (sirolimus-steroid)
Number of subjects: 430
Study 15147430 — intervention group
Group type: COMPARATOR
Intervention: CsA-Withdrawal (SRL‐ST)
Number of subjects: 430
Study 11199944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 160 mg/day
Number of subjects: 115
Study 11199944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 120 mg/day
Number of subjects: 115
Study 11199944 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone 40 mg/day
Number of subjects: 115
Study 11199944 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone 80 mg/day
Number of subjects: 115
Study 11199944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 9849281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 180
Study 9849281 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 180
Study 9849281 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 180
Study 9849281 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 180
Study 9849281 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 180
Study 8291732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil-lorazepam
Number of subjects: 21
Study 8291732 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 21
Study 8291732 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 21
Study 8291732 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 21
Study 8291732 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane and Isoflurane
Number of subjects: 21
Study 3188847 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-palladium alloy Albacast
Number of subjects: 23
Study 3188847 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-gold alloy Midas
Number of subjects: 23
Study 3188847 — intervention group
Group type: COMPARATOR
Intervention: High-gold type-3 alloy JS C
Number of subjects: 23
Study 31488144 — intervention group
Group type: EXPERIMENTAL
Intervention: Service transformation along the key foci (early identification, rapid access, appropriate care, elimination of age-based transitions, engagement of youth and families)
Number of subjects: 14
Study 31488144 — intervention group
Group type: EXPERIMENTAL
Intervention: Service transformation along the key foci
Number of subjects: 14
Study 28784701 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) supplementation (10 billion CFU and 225 mg of inulin)
Number of subjects: 184
Study 28784701 — intervention group
Group type: COMPARATOR
Intervention: Control group (325 mg of inulin alone)
Number of subjects: 184
Study 26270573 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet
Number of subjects: 52
Study 26270573 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (control group)
Number of subjects: 52
Study 24084626 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional abciximab
Number of subjects: 452
Study 24084626 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Number of subjects: 452
Study 22117995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen added to lidocaine in IVRA
Number of subjects: 45
Study 22117995 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 45
Study 20126911 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP with tetracycline‐loaded absorbent membrane
Number of subjects: 24
Study 20126911 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 24
Study 16565636 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced depression treatment
Number of subjects: 198
Study 16565636 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 198
Study 15169741 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 20 ng kg(‐1) min(‐1) i.v. during anaesthesia
Number of subjects: 14
Study 15169741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PGE1)
Number of subjects: 14
Study 10943869 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day intravenous administration of anti‐IL‐10 monoclonal antibody (B‐N10) for 21 consecutive days
Number of subjects: 6
Study 9077368 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (7 sessions during weeks 10 and 11)
Number of subjects: 33
Study 9077368 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture treatment)
Number of subjects: 33
Study 8336991 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery techniques (matched intervention)
Number of subjects: 0
Study 8336991 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory focusing (mismatched intervention)
Number of subjects: 0
Study 8336991 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 0
Study 3944815 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 1.2 mg
Number of subjects: 115
Study 3944815 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 1.8 mg
Number of subjects: 115
Study 3944815 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.6 mg
Number of subjects: 115
Study 3944815 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.9 mg
Number of subjects: 115
Study 29798500 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized dermatophagoides farinae drops for 12 months
Number of subjects: 92
Study 29798500 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SLIT)
Number of subjects: 92
Study 27348641 — intervention group
Group type: EXPERIMENTAL
Intervention: Arnica ointment 10%
Number of subjects: 136
Study 27348641 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 136
Study 25009971 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training Group (ATG, n=19)
Number of subjects: 59
Study 25009971 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Aerobic and Resistance Training Group (MTG, n=20)
Number of subjects: 59
Study 25009971 — intervention group
Group type: COMPARATOR
Intervention: Control Group (n=20)
Number of subjects: 59
Study 22363015 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term multifactor cardiovascular disease (CVD) risk reduction program
Number of subjects: 0
Study 22363015 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 20878045 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month exercise programme (n = 56)
Number of subjects: 105
Study 20878045 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 49)
Number of subjects: 105
Study 18674411 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules (3-12 mg/day)
Number of subjects: 710
Study 18674411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study 18674411 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules (3-12 mg/day) in older patients (>=75 years old)
Number of subjects: 710
Study 18674411 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules (3-12 mg/day) in younger patients (less than 75 years old)
Number of subjects: 710
Study 18674411 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules (3-12 mg/day) in patients with medial temporal atrophy
Number of subjects: 710
Study 16130427 — intervention group
Group type: EXPERIMENTAL
Intervention: thiotropium bromide, 18 microg/day
Number of subjects: 20
Study 16130427 — intervention group
Group type: COMPARATOR
Intervention: ipratropium bromide, 160 microg/day
Number of subjects: 20
Study 14650953 — intervention group
Group type: COMPARATOR
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 0
Study 14650953 — intervention group
Group type: COMPARATOR
Intervention: Preoperative chemotherapy
Number of subjects: 0
Study 14650953 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy
Number of subjects: 0
Study 10665980 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin and its derivatives
Number of subjects: 0
Study 9258016 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathways and dedicated vascular wing implementation
Number of subjects: 0
Study 9258016 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 1510255 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg of metoclopramide
Number of subjects: 102
Study 1510255 — intervention group
Group type: COMPARATOR
Intervention: Saline solution placebo
Number of subjects: 102
Study 6207158 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course of ARA‐AMP (4 weeks)
Number of subjects: 31
Study 6207158 — intervention group
Group type: EXPERIMENTAL
Intervention: Long course of ARA‐AMP (7 to 12 weeks)
Number of subjects: 31
Study 30693979 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe‐Gly (60 mg Fe/kg)
Number of subjects: 810
Study 30693979 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe‐Gly (60, 80 mg Fe/kg)
Number of subjects: 810
Study 30693979 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe‐Gly (40 mg Fe/kg)
Number of subjects: 810
Study 30693979 — intervention group
Group type: COMPARATOR
Intervention: FeSO4 (60 mg Fe/kg)
Number of subjects: 810
Study 30227360 — intervention group
Group type: EXPERIMENTAL
Intervention: Public participation process and tailored traffic enforcement program
Number of subjects: 12236
Study 30227360 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12236
Study 27456147 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunneled subcutaneous perineural catheter
Number of subjects: 338
Study 27456147 — intervention group
Group type: COMPARATOR
Intervention: Control group with adhesive strips
Number of subjects: 338
Study 24268590 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (598 participants)
Number of subjects: 1190
Study 24268590 — intervention group
Group type: COMPARATOR
Intervention: Placebo (592 participants)
Number of subjects: 1190
Study 24268590 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (participants enrolled <48h since symptom onset)
Number of subjects: 1190
Study 24268590 — intervention group
Group type: COMPARATOR
Intervention: Placebo (participants enrolled <48h since symptom onset)
Number of subjects: 1190
Study 24268590 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (all swab specimens, n=1134)
Number of subjects: 1190
Study 24268590 — intervention group
Group type: COMPARATOR
Intervention: Placebo (all swab specimens, n=1134)
Number of subjects: 1190
Study 24268590 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (participants enrolled 48h or longer since illness onset)
Number of subjects: 1190
Study 24268590 — intervention group
Group type: COMPARATOR
Intervention: Placebo (participants enrolled 48h or longer since illness onset)
Number of subjects: 1190
Study 24268590 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (overall)
Number of subjects: 1190
Study 22634329 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilliatt's pneumatic tourniquet test (supra-systolic pressure)
Number of subjects: 49
Study 22634329 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilliatt's pneumatic tourniquet test (infra-systolic pressure)
Number of subjects: 49
Study 22634329 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilliatt's test
Number of subjects: 49
Study 22634329 — intervention group
Group type: COMPARATOR
Intervention: Phalen test
Number of subjects: 49
Study 22634329 — intervention group
Group type: COMPARATOR
Intervention: Durkan test
Number of subjects: 49
Study 20478960 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliable immunisation camp with small incentives (intervention B); 382 children from 30 villages
Number of subjects: 1640
Study 20478960 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliable immunisation camp without incentives (intervention A); 379 children from 30 villages
Number of subjects: 1640
Study 20478960 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention); 860 children in 74 villages
Number of subjects: 1640
Study 17593136 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 16
Study 17593136 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Dyspepsia (FD)
Number of subjects: 16
Study 16198653 — intervention group
Group type: EXPERIMENTAL
Intervention: OATP 1B1 *1b/*1b genotype
Number of subjects: 24
Study 16198653 — intervention group
Group type: EXPERIMENTAL
Intervention: OATP 1B1 *1a/*1a or *1a/*1b genotype
Number of subjects: 24
Study 16198653 — intervention group
Group type: EXPERIMENTAL
Intervention: OATP 1B1 *1a/*15 or *1b/*15 genotype
Number of subjects: 24
Study 12822088 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (resection and drainage procedures)
Number of subjects: 72
Study 12822088 — intervention group
Group type: COMPARATOR
Intervention: Endotherapy (sphincterotomy, stenting, and/or stone removal)
Number of subjects: 72
Study 12822088 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 72
Study 12822088 — intervention group
Group type: COMPARATOR
Intervention: Endotherapy
Number of subjects: 72
Study 11783209 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick-acting Kuijie powder (QAKJP) retention enema
Number of subjects: 234
Study 11783209 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine orally (control)
Number of subjects: 234
Study 7791603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cover stories involving different pairs of element sets (e.g., objects and people)
Number of subjects: 0
Study 7791603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cover stories involving similar sets of people (e.g., doctors and doctors)
Number of subjects: 0
Study 7791603 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer of problem-solving skills
Number of subjects: 0
Study 1787651 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% branched-chain amino acid (BCAA) solution
Number of subjects: 0
Study 1787651 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study 6989682 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide/amiloride (Moduretic)
Number of subjects: 25
Study 6989682 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 25
Study 31398726 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based intervention (LanguageLinks: Syntax Assessment and Intervention®; Laureate Learning Systems, Inc., 2013)
Number of subjects: 37
Study 31398726 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37
Study 31564503 — intervention group
Group type: EXPERIMENTAL
Intervention: MID‐O2 (midazolam 1 mg kg‐1 IM)
Number of subjects: 9
Study 31564503 — intervention group
Group type: EXPERIMENTAL
Intervention: SAL‐N2O (saline IM and isoflurane with 50% nitrous oxide)
Number of subjects: 9
Study 31564503 — intervention group
Group type: COMPARATOR
Intervention: SAL‐O2 (saline IM and isoflurane‐oxygen)
Number of subjects: 9
Study 28034985 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal, isometric exercise for three minutes
Number of subjects: 58
Study 28034985 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive family environments
Number of subjects: 58
Study 28034985 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative and chronic pain-present family environments
Number of subjects: 58
Study 28034985 — intervention group
Group type: EXPERIMENTAL
Intervention: Situational catastrophizing and negative mood state
Number of subjects: 58
Study 25879193 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Care
Number of subjects: 0
Study 25879193 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 0
Study 23617535 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygium surgery using conjunctival autograft technique
Number of subjects: 21
Study 21318929 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Action programme
Number of subjects: 510
Study 21318929 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 510
Study 19947365 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of the virus vaccine and chemotherapy (group A)
Number of subjects: 84
Study 19947365 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy with the vaccine alone (group B)
Number of subjects: 84
Study 19947365 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy regimen identical with that used in group A (group C)
Number of subjects: 84
Study 17456483 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 20 mg tid for 4 weeks
Number of subjects: 51
Study 17456483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 15689099 — intervention group
Group type: EXPERIMENTAL
Intervention: Four questions on knowledge and beliefs about smoking, standardized verbal advice against smoking, and a leaflet
Number of subjects: 387
Study 15689099 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 387
Study 12953348 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg coadministered with digoxin on Day 7
Number of subjects: 12
Study 12953348 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 80 mg coadministered with digoxin on Days 8 to 11
Number of subjects: 12
Study 9854128 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal laparoscopic hernia repair
Number of subjects: 0
Study 9854128 — intervention group
Group type: COMPARATOR
Intervention: Open tension‐free hernia repair
Number of subjects: 0
Study 8682031 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide 100 mg for paroxysmal supraventricular tachycardia
Number of subjects: 335
Study 8682031 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide 200 mg for paroxysmal atrial fibrillation
Number of subjects: 335
Study 8682031 — intervention group
Group type: COMPARATOR
Intervention: Propafenone 450 mg for paroxysmal supraventricular tachycardia
Number of subjects: 335
Study 8682031 — intervention group
Group type: COMPARATOR
Intervention: Propafenone 450 mg for paroxysmal atrial fibrillation
Number of subjects: 335
Study 2211279 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk coupon incentive
Number of subjects: 534
Study 2211279 — intervention group
Group type: EXPERIMENTAL
Intervention: Gift for teenage mother incentive
Number of subjects: 534
Study 2211279 — intervention group
Group type: COMPARATOR
Intervention: No incentive (control)
Number of subjects: 534
Study 508609 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease skin conductance training
Number of subjects: 33
Study 508609 — intervention group
Group type: COMPARATOR
Intervention: Increase skin conductance training
Number of subjects: 33
Study 31584063 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% fat milk
Number of subjects: 55
Study 31584063 — intervention group
Group type: EXPERIMENTAL
Intervention: 31% fat cheddar cheese
Number of subjects: 55
Study 31584063 — intervention group
Group type: COMPARATOR
Intervention: No dairy (control diet)
Number of subjects: 55
Study 30680980 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized 2% lidocaine (group L)
Number of subjects: 90
Study 30680980 — intervention group
Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 90
Study 30680980 — intervention group
Group type: COMPARATOR
Intervention: Air (group A)
Number of subjects: 90
Study 27856630 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐fluciclovine PET/CT
Number of subjects: 24
Study 27856630 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study 26404367 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Satiety Phenotype (LSP)
Number of subjects: 30
Study 26404367 — intervention group
Group type: COMPARATOR
Intervention: High Satiety Phenotype (HSP)
Number of subjects: 30
Study 23460036 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysensitisation (>2 sensitisations)
Number of subjects: 784
Study 23460036 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive IgE test for one or more allergens
Number of subjects: 784
Study 23460036 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 9-13 years
Number of subjects: 784
Study 23460036 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysensitised children
Number of subjects: 784
Study 23460036 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sensitised children
Number of subjects: 784
Study 20628752 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue welding tonsillectomy (TW-TE)
Number of subjects: 60
Study 20628752 — intervention group
Group type: COMPARATOR
Intervention: Monopolar electrocautery tonsillectomy (monopolar-TE)
Number of subjects: 60
Study 19687522 — intervention group
Group type: EXPERIMENTAL
Intervention: Care from a nurse specialised in diabetes (NSD)
Number of subjects: 84
Study 19687522 — intervention group
Group type: COMPARATOR
Intervention: Care from an internist (Control)
Number of subjects: 84
Study 17336817 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (mean of 1.66 hours)
Number of subjects: 20
Study 17336817 — intervention group
Group type: COMPARATOR
Intervention: Standard care (holding the infant swaddled in blankets)
Number of subjects: 20